Masimo Co. (NASDAQ:MASI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Masimo Co. (NASDAQ:MASI) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $179.67.

Several brokerages have issued reports on MASI. Raymond James raised their price objective on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 price target (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. BTIG Research raised their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Wells Fargo & Company upped their price target on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th.

Masimo Price Performance

Shares of NASDAQ MASI opened at $165.55 on Wednesday. The stock’s 50-day simple moving average is $166.17 and its 200-day simple moving average is $137.76. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm has a market capitalization of $8.86 billion, a PE ratio of 114.17 and a beta of 1.01. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $180.97.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.63 EPS. As a group, equities research analysts forecast that Masimo will post 4.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Masimo

A number of large investors have recently bought and sold shares of the company. NBC Securities Inc. boosted its holdings in shares of Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 73 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 200 shares during the period. GAMMA Investing LLC boosted its holdings in Masimo by 136.5% in the 4th quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider’s stock valued at $77,000 after purchasing an additional 269 shares in the last quarter. HHM Wealth Advisors LLC increased its position in Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after purchasing an additional 125 shares during the period. Finally, Headlands Technologies LLC acquired a new position in Masimo during the 2nd quarter worth approximately $109,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.